IDEXX Laboratories, Inc. $IDXX Shares Sold by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 931 shares of the company’s stock after selling 214 shares during the period. Moloney Securities Asset Management LLC’s holdings in IDEXX Laboratories were worth $499,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mutual of America Capital Management LLC lifted its position in shares of IDEXX Laboratories by 79.6% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after acquiring an additional 8,609 shares during the last quarter. Golden State Wealth Management LLC lifted its position in shares of IDEXX Laboratories by 3,766.7% during the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after acquiring an additional 113 shares during the last quarter. Plato Investment Management Ltd lifted its position in shares of IDEXX Laboratories by 37.1% during the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after acquiring an additional 835 shares during the last quarter. Genesis Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $215,000. Finally, ORG Wealth Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $273,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.4%

Shares of NASDAQ:IDXX opened at $640.85 on Friday. The stock has a market capitalization of $51.27 billion, a PE ratio of 53.36, a P/E/G ratio of 4.15 and a beta of 1.58. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12. The firm has a fifty day moving average price of $638.40 and a 200 day moving average price of $559.16. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. IDEXX Laboratories’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Michael Lane sold 8,411 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the sale, the executive vice president directly owned 7,132 shares in the company, valued at approximately $4,477,041.68. This represents a 54.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director M Anne Szostak sold 2,187 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the sale, the director owned 262 shares of the company’s stock, valued at $169,600.46. This represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock valued at $34,293,468 in the last three months. 0.98% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

IDXX has been the topic of several recent analyst reports. BTIG Research boosted their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. UBS Group initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, October 1st. They set a “neutral” rating and a $720.00 target price on the stock. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, August 4th. Leerink Partners boosted their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.